Payment overview · 2025
General Payments
$305.52
16 reported records · 10 companies
Healthcare provider profile · identity verified
Byron Shane Thomas, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · WHITESBURG, KY · NPI 1952564502
Verified facts
What the public records show
CMS Open Payments records show Byron Shane Thomas, D.O. received $305.52 in general payments during 2025 across 16 reported records.
Grifols USA, LLC accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $73.75 | 24.1% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $59.24 | 19.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.19 | 11.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.64 | 8.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.50 | 7.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.04 | 7.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.00 | 6.5% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $17.84 | 5.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.94 | 5.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.38 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $305.52 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $73.75 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.34 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $35.19 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $17.84 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
48 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
150 | 42 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
107 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 699 | 148 |
| Atorvastatin Calcium | Atorvastatin Calcium | 658 | 156 |
| Levothyroxine Sodium | Levothyroxine Sodium | 606 | 125 |
| Lisinopril | Lisinopril | 552 | 135 |
| Omeprazole | Omeprazole | 461 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 424 | 111 |
| Metformin Hcl | Metformin Hcl | 416 | 94 |
| Potassium Chloride | Potassium Chloride | 412 | 108 |
| Furosemide | Furosemide | 356 | 88 |
| Losartan Potassium | Losartan Potassium | 330 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 320 | 89 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 297 | 79 |
| Montelukast Sodium | Montelukast Sodium | 296 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 282 | 65 |
| Hydrochlorothiazide | Hydrochlorothiazide | 279 | 64 |
| Pravastatin Sodium | Pravastatin Sodium | 279 | 58 |
| Famotidine | Famotidine | 256 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 255 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 249 | 65 |
| Sertraline Hcl | Sertraline Hcl | 249 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 234 | 67 |
| Glipizide | Glipizide | 232 | 53 |
| Trazodone Hcl | Trazodone Hcl | 228 | 53 |
| Buspirone Hcl | Buspirone Hcl | 223 | 57 |
| Meloxicam | Meloxicam | 222 | 55 |
| Clopidogrel | Clopidogrel Bisulfate | 204 | 48 |
| Prednisone | Prednisone | 203 | 99 |
| Eliquis | Apixaban | 202 | 38 |
| Gabapentin | Gabapentin | 184 | 30 |
| Simvastatin | Simvastatin | 182 | 48 |
| Carvedilol | Carvedilol | 179 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 169 | 85 |
| Mounjaro | Tirzepatide | 162 | 29 |
| Farxiga | Dapagliflozin Propanediol | 150 | 42 |
| Jardiance | Empagliflozin | 139 | 26 |
| Bumetanide | Bumetanide | 134 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 133 | 40 |
| Cefdinir | Cefdinir | 131 | 108 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 131 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 26 |
| Pregabalin | Pregabalin | 127 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 118 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 115 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 113 | 34 |
| Allopurinol | Allopurinol | 111 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 109 | 40 |
| Ibuprofen | Ibuprofen | 109 | 36 |
| Amitriptyline Hcl | Amitriptyline Hcl | 107 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 107 | 21 |
| Ozempic | Semaglutide | 107 | 25 |
| Xarelto | Rivaroxaban | 107 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 106 | 33 |
| Sucralfate | Sucralfate | 102 | 20 |
| Spironolactone | Spironolactone | 98 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 97 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 96 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 89 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 29 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 85 | 28 |
| Methocarbamol | Methocarbamol | 85 | 22 |
| Valsartan | Valsartan | 84 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 83 | 23 |
| Vascepa | Icosapent Ethyl | 82 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 81 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 80 | 65 |
| Tramadol Hcl | Tramadol Hcl | 80 | 30 |
| Fenofibrate | Fenofibrate | 79 | 21 |
| Ezetimibe | Ezetimibe | 78 | 15 |
| Ondansetron Odt | Ondansetron | 75 | 33 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 74 | 16 |
| Nystatin | Nystatin | 70 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 18 |
| Nifedipine Er | Nifedipine | 68 | 17 |
| Azithromycin | Azithromycin | 67 | 53 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 67 | 11 |
| Levetiracetam | Levetiracetam | 66 | 12 |
| Januvia | Sitagliptin Phosphate | 64 | 16 |
| Mirtazapine | Mirtazapine | 64 | 12 |
| Donepezil Hcl | Donepezil Hcl | 61 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 61 | 17 |
| Trulicity | Dulaglutide | 60 | 14 |
| Atenolol | Atenolol | 59 | 18 |
| Amoxicillin | Amoxicillin | 54 | 49 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 54 | 12 |
| Fluconazole | Fluconazole | 54 | 31 |
| Naproxen | Naproxen | 52 | 14 |
| Celecoxib | Celecoxib | 51 | 14 |
| Lovastatin | Lovastatin | 51 | 11 |
| Nitroglycerin | Nitroglycerin | 51 | 20 |
| Promethazine Hcl | Promethazine Hcl | 49 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 48 | suppressed |
| Linzess | Linaclotide | 48 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | 14 |
| Alendronate Sodium | Alendronate Sodium | 47 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | 11 |
| Finasteride | Finasteride | 45 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 44 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | 19 |
| Colchicine | Colchicine | 43 | 13 |
| Clonazepam | Clonazepam | 42 | 11 |
| Lamotrigine | Lamotrigine | 41 | suppressed |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 41 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 13 |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 39 | 12 |
| Theophylline Er | Theophylline Anhydrous | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 29 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 35 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 26 |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | 11 |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 27 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | 11 |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | 12 |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Ranolazine Er | Ranolazine | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 26 |
| Torsemide | Torsemide | 27 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Desloratadine | Desloratadine | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Tradjenta | Linagliptin | 23 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 15 |
| Zafirlukast | Zafirlukast | 22 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 13 |
| Megestrol Acetate | Megestrol Acetate | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 18 |
| Lagevrio (Eua) | Molnupiravir | 19 | 19 |
| Novolog | Insulin Aspart | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 14 |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Levonest | Levonorgestrel/Ethin.Estradiol | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Xiidra | Lifitegrast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $305.52 · 16 records | Grifols USA, LLC | AIRSUPRA, BREZTRI, CAPLYTA, CRYSVITA, Cologuard Collection Kit, Prolastin-C Liquid, REPATHA, VOQUEZNA, VRAYLAR, Wegovy, ZERBAXA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error